Literature DB >> 1618176

3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents.

C P Taylor1, M G Vartanian, R Andruszkiewicz, R B Silverman.   

Abstract

Recently we showed that 3-alkyl-4-aminobutanoic acids are in vitro activators of brain L-glutamic acid decarboxylase (GAD) that show anticonvulsant activity. Since activation of GAD leads to increased concentrations of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in vitro, these compounds could represent a new class of anticonvulsant agents. Here it is shown that 3-alkylglutamic acid analogues also activate GAD and that all of the compounds in both series are active anticonvulsant agents against low intensity electroshock in mice. The most active compound, 3-isobutyl GABA, was tested further against maximal electroshock in mice and was shown to be very potent after both intravenous and oral administration without causing ataxia. It is not known if brain GABA levels are elevated in vivo by administration of these compounds or if the mechanism of anticonvulsant activity is related to their ability to activate GAD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618176     DOI: 10.1016/0920-1211(92)90044-t

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  11 in total

Review 1.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

3.  The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T ¹H-MRS study.

Authors:  Kejia Cai; Ravi Pr Nanga; Lisa Lamprou; Claudia Schinstine; Mark Elliott; Hari Hariharan; Ravinder Reddy; C Neill Epperson
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

4.  Plasticity of rat central inhibitory synapses through GABA metabolism.

Authors:  D Engel; I Pahner; K Schulze; C Frahm; H Jarry; G Ahnert-Hilger; A Draguhn
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

5.  Influence of short-lasting bilateral clamping of carotid arteries (BCCA) on GABA turnover in rat brain structures.

Authors:  M Sieklucka; W Löscher; C Heim; K H Sontag
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

6.  Synthesis and evaluation of amino analogues of valproic acid.

Authors:  K R Scott; S Adesioye; P B Ayuk; I O Edafiogho; D John; P Kodwin; T Maxwell-Irving; J A Moore; J M Nicholson
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

Review 7.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

8.  Pregabalin in neuropathic pain: evidences and possible mechanisms.

Authors:  Vivek Verma; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

9.  Silicon-containing GABA derivatives, silagaba compounds, as orally effective agents for treating neuropathic pain without central-nervous-system-related side effects.

Authors:  Hiroshi Fukasawa; Hideaki Muratake; Ai Ito; Hideyuki Suzuki; Yohei Amano; Marina Nagae; Kiyoshi Sugiyama; Koichi Shudo
Journal:  ACS Chem Neurosci       Date:  2014-04-30       Impact factor: 4.418

10.  Altered expression of the voltage-gated calcium channel subunit α₂δ-1: a comparison between two experimental models of epilepsy and a sensory nerve ligation model of neuropathic pain.

Authors:  M Nieto-Rostro; G Sandhu; C S Bauer; P Jiruska; J G R Jefferys; A C Dolphin
Journal:  Neuroscience       Date:  2014-03-15       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.